Targets › HERVK
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Feb 2028.
Open in Phaseline: the race on HERVK, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Immunomic Therapeutics | ITI-5000 Self-amplifying RNA vaccine targeting HERV-K and CT83 fused with LAMP-1 | HERVK, CT83, LAMP1 | Phase 1 | Triple Negative Breast Cancer (TNBC) | Feb 2028 |
Triple Negative Breast Cancer (TNBC) (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.